Business
Immunome Announces Submission of New Drug Application to U.S. FDA for Varegacestat for the Treatment of Adults with Desmoid Tumors
BOTHELL, Wash., April 29, 2026--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for varegacestat, an investigational, oral, once-daily gamma secretase inhibitor (GSI), for the treatment of adults with desmoid tumors.
About this update from Immunome, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":333,"url":"https://media.zenfs.com/en/business-wire.com/71a49370ae6433bc38e2cef543460e28"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/HLhY5PrRZnEoMI833UNQ7Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTY2Ng--/https://media.zenfs.com/en/business-wire.com/71a49370ae6433bc38e2cef543460e28","width":480,"height":333}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"New Drug Application (NDA) supported by positive Phase 3 RINGSIDE results, including significant improvement in progression-free survival vs. placebo (hazard ratio = 0.16, p<0.0001)","length":184,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Trial also met all key secondary endpoints, with varegacestat delivering an objective response rate of 56%","length":106,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Detailed Phase 3 RINGSIDE data selected for oral presentation at the 2026 ASCO Annual Meeting","length":93,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":383,"olType":false},{"type":"text","content":"BOTHELL, Wash., April 29, 2026--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for varegacestat, an investigational, oral, once-daily gamma secretase inhibitor (GSI), for the treatment of adults with desmoid tumors.","length":434,"tagName":"p"},{"type":"text","content":""The varegacestat NDA submission marks an important milestone for Immunome. It reflects the strength of the RINGSIDE dataset and the commitment of the team advancing this program," said Clay B. Siegall, Ph.D., President and Chief Executive Officer of Immunome. "We believe varegacestat has the potential to provide adults with progressing desmoid tumors with a meaningful new oral treatment option, and we are grateful to the patients, families, investigators and study site teams whose participation made this submission possible."","length":552,"tagName":"p"},{"type":"text","content":"The NDA is supported by positive results from the global, randomiz...